Business context and reporting period
The supplied filing is Organovo Holdings, Inc.’s Form 10-Q, not a filing identified as Vivosim Labs, Inc. It covers the quarter and six months ended September 30, 2015; the quarter is the second quarter of Organovo’s fiscal 2016. Organovo is an early-commercial-stage developer of 3D human tissues for drug research, biological research, and potential therapeutic use. Its first commercial product, exVive3D Human Liver Tissue, was launched in November 2014. The filing reports that commercial operations had not yet generated significant revenue.
Financial results and position
Amounts below are in millions of dollars except per-share data. The filing does not provide a clear gross-profit or gross-margin figure.
| Metric | Three months ended Sep. 30, 2015 | Three months ended Sep. 30, 2014 | Six months ended Sep. 30, 2015 | Six months ended Sep. 30, 2014 |
|---|---|---|---|---|
| Revenue | $0.301 | $0.050 | $0.607 | $0.149 |
| Operating expenses | $11.585 | $9.006 | $20.349 | $15.515 |
| Operating loss | $(11.284) | $(8.956) | $(19.742) | $(15.366) |
| Net loss | $(11.257) | $(8.858) | $(19.748) | $(15.291) |
| Net loss per share | $(0.12) | $(0.11) | $(0.23) | $(0.19) |
Second-quarter revenue included $0.187 million of product and service revenue, $0.019 million of collaboration revenue, and $0.095 million of grants. For the six-month period, product and service revenue was $0.396 million, collaboration revenue $0.033 million, and grants $0.178 million.
- Cash and liquidity: Cash and cash equivalents were $76.863 million at September 30, 2015, versus $50.142 million at March 31, 2015. Working capital was $72.3 million, with current assets of $77.825 million and current liabilities of $5.518 million.
- Cash flows: Six-month operating cash use was $14.921 million, investing cash use was $1.571 million, and financing cash provided was $43.213 million. Cash increased by $26.721 million.
- Debt and obligations: No material borrowing balance is shown; capital lease obligations were zero at September 30. Operating lease commitments totaled $6.564 million. Deferred revenue totaled $1.409 million.
- Equity: A June 2015 public offering generated approximately $43.1 million net and issued 10,838,750 shares. There were 92,327,772 shares outstanding at September 30 and 92,413,710 at October 30.
Material changes versus the prior comparable periods
- Quarterly revenue rose by $0.251 million from a small prior-year base, primarily reflecting commercial liver-tissue research services launched after November 2014. Six-month revenue increased by $0.458 million, including $0.396 million of product and service revenue and higher grant revenue; lower collaboration revenue partly offset the increase.
- Quarterly operating expenses rose approximately 29% to $11.6 million; six-month expenses increased approximately 31% to $20.3 million. Higher research and development spending and expanded administrative and commercial infrastructure drove the increases.
- Six-month operating cash use increased $5.2 million year over year, while investing outlays rose to $1.6 million, mainly for facility build-out. The June equity offering materially increased cash and stockholders’ equity.
- Research and development expense increased 47% for both the quarter and six-month comparison periods described by management, reflecting staffing, supplies, contract services, and facility costs. Management cited average R&D headcount of 57 in the quarter versus 41 a year earlier.
Outlook, risks, contingencies, and unusual items
- Management stated that available cash and expected receipts were sufficient to fund operations as then planned for at least the next 12 months. No quantified revenue, earnings, or cash-flow guidance was provided.
- Key risks include the company’s early commercial stage, limited revenue, the challenge of achieving product development and market acceptance, continued operating cash burn, and the possibility that future financing may be unavailable or dilutive. Management warned that inadequate funding could require reductions or delays to development programs. The filing says risk factors had not materially changed from the prior Form 10-K.
- In August 2015, Organovo settled its disputes with Spencer Trask Ventures and paid $150,000; the parties dismissed their claims with prejudice. The company said the settlement did not adversely affect its business, results, liquidity, or financial condition.
- Stock-based compensation was $3.952 million for the six months, a significant noncash expense. The company also disclosed $17.150 million of unrecognized stock-option compensation cost expected to be recognized over a weighted-average 2.79 years.
- Subsequent to quarter-end, the company adopted a severance and change-in-control plan for executives and certain key employees, including specified severance benefits and accelerated equity vesting for qualifying change-in-control terminations.
Important facts for investors to verify
- Confirm the issuer and period: this source is Organovo Holdings, Inc.’s quarter ended September 30, 2015, despite the request metadata naming Vivosim Labs and 2015 Q2.
- Track whether product and research-service revenue grows enough to offset rising operating expenses and cash burn; this filing reports no clear gross-margin measure.
- Assess cash runway against the reported six-month operating cash use, facility spending, and $6.564 million of lease commitments.
- Review potential dilution from additional financing, outstanding options and warrants, and the amended equity incentive plan.
- Monitor the timing and collectability of deferred revenue and collaboration or grant receipts, as well as execution of the company’s commercialization plans.